ReviewDiscover oncology2025
Breast cancer as the first primary malignancy: clinical pathological characteristics of common cancer combinations.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A case report of synchronous bilateral breast cancer with distinct histological subtypes and favorable long-term survival.Frontiers in oncology · 2026Article
- Case Report: Metachronous pancreatic adenocarcinoma following HER2-positive breast cancer and the implications of non-BRCA germline variants with TP53-mutant disease.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the continuous rise in breast cancer incidence and significant improvement in patient survival, the risk of developing Multiple Primary Malignancies (MPMs) has garnered increasing attention. As the most common malignant tumor in women, breast cancer has a complex pathogenesis involving multiple factors such as genetic predisposition, treatment exposure, and interactions between hormonal pathways. These tumors are often difficult to distinguish from metastases or recurrences in clinical practice, frequently leading to delays in diagnosis and treatment, thereby affecting patient prognosis. Therefore, predicting the occurrence of second primary cancer (SPC) in cancer survivors is important in clinical diagnosis and treatment. This review synthesizes evidence from global cohorts, with an emphasis on Asian populations where relevant, to provide a narrative review of the research progress on Breast Cancer First Primary Malignancy (BCFPM). It focuses on the epidemiological characteristics, mechanisms (including the field cancerization theory and multifocal origin theory), and clinicopathological features of common cancer combinations. The aim is to identify high-risk populations for breast cancer and propose follow-up strategies, providing a scientific basis for the development of clinical prevention and intervention strategies, as well as early diagnosis and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.